A quick analysis of the top performing fund managers over the past few years clearly indicates that the small cap sector has been the place to be if you wanted to generate massive returns.
Although some fund managers are suggesting that it might be time to rotate back into the bigger end of the market, I still think investing in the small cap sector will provide investors with the best chance of achieving double-digit returns over the next 12 months or so.
On that basis, I have selected three small cap shares that I think growth-hungry investors could consider with a little more research:
RCG Corporation Ltd (ASX: RCG)
RCG is a holding company for a number of active lifestyle and footwear businesses including The Athlete's Foot, Skechers and Platypus. As highlighted by the chart below, earnings growth has really accelerated over the last year and this was driven primarily through strong like-for-like sales growth and a full contribution to earnings from the recently acquired Accent Group.
Importantly, RCG is expected to carry its earnings momentum through FY17 and is targeting EBITDA growth of around 50%. The shares trade on a forward price-to-earnings (P/E) ratio of around 18 and are expected to provide a dividend yield of around 4.2%.
MNF Group Ltd (ASX: MNF)
MNF (formerly My Net Fone) is a fast-growing telecommunications company that provides voice over internet protocol (VoIP) data and video services. One of the major differentiating factors of MNF compared to other traditional telco companies is the ease with which it has expanded into new territories to create a global network.
The shares currently trade on a fairly lofty multiple, although this can be partly justified when you consider the company has delivered compounded earnings per share growth of around 20% each year, over the last five years. More importantly, MNF has a long runway of growth ahead of it as many of its target customers are yet to be fully serviced.
Capilano Honey Ltd (ASX: CZZ)
Shares of the iconic Australian honey producer have been under pressure since announcing a $16.8 million capital raising in late May, although the company has continued to deliver pretty healthy revenue and profit growth since then. Capilano has now embarked on a number of new initiatives aimed at exploiting the company's market-leading position including a much bigger focus on the 'Manuka' brand which will be specifically targeted towards the health and wellness market in Australia and China. If Capilano can capitalise on this opportunity, I believe the current share price presents an excellent buying opportunity as the shares currently trade on an undemanding P/E ratio of 17.
